Paclitaxel Interrupts TGF-β1 Signaling Between Gallbladder Epithelial Cells and Myofibroblasts

Choi, Ho Soon; Savard, Christopher E.; Choi, Jae Woon; Kuver, Rahul; Lee, Sum P.

doi:10.1016/j.jss.2006.12.558

Cited by 25 publications

(27 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIBEpiCs were cultured in RIMP1640 supplemented with 10% fetal bovine serum (FBS), at 37 C in a 5% CO 2 humidified atmosphere. Because TGF-b1 mRNA was markedly up-regulated when the concentration of LPS reached 2 mg/mL in vitro [8], cells were stimulated with LPS at a concentration of 2 mg/mL at different time points.…”

Section: Cell Culturementioning

confidence: 99%

LPS-Induced Epithelial-Mesenchymal Transition of Intrahepatic Biliary Epithelial Cells

Zhao

Yang²,

Cheng

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

Section: Cell Culturementioning

confidence: 99%

LPS-Induced Epithelial-Mesenchymal Transition of Intrahepatic Biliary Epithelial Cells

Zhao

Yang²,

Cheng

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

“…Moreover, it has been reported that paclitaxel ameliorates fibrosis in hepatic stellate cells and renal fibrosis through the inhibition of TGF-β/Smad activity (6,7). Paclitaxel also interrupts TGF-β1 signaling between gallbladder epithelial cells and myofibroblasts (19). Taghian et al reported that paclitaxel decreases interstitial fluid pressure and improves oxygenation in breast cancer tissues in patients treated with neoadjuvant chemotherapy and that patients with hypoxic tumors and/or tumors with high interstitial fluid pressure may start with paclitaxel chemotherapy to improve their physiological status (20).…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report

Tajima¹,

Ohta²,

Shinbashi³

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract.A 56-year-old female with metastatic gallbladder cancer involving the liver and stenosis of the hilar bile duct was treated with gemcitabine (1,000 mg/m 2 ) plus S-1 (60 mg/m 2 ). After 9 cycles of therapy, CT showed evidence of stable disease; however, the serum CEA level was increased. Therefore, the chemotherapy regimen was changed to weekly low-dose paclitaxel (60 mg/m 2 ). After 12 cycles of therapy, paclitaxel was reduced to 30 mg/m 2 as the patient developed neutropenia. The patient completed 32 cycles of therapy, and the tumor was reduced in size and marked improvement in bile duct stenosis was noted without any impairment in quality of life. The patient succumbed to the disease 25 months after treatment was initiated. Thus, in this case paclitaxel was more effective than gemcitabine plus S-1. Palliative chemotherapy with paclitaxel after failure of gemcitabine and 5-FU was well-tolerated; therefore, it may be an effective treatment for biliary tract cancer (BTC). A phase I study of palliative chemotherapy with weekly low-dose paclitaxel following gemcitabine (plus cisplatin) and 5-FU is currently in progress in patients with unresectable or recurrent BTC.

show abstract

“…Low-dose paclitaxel (71)(72)(73)(74), metformin (75)(76)(77), angiotensin receptor blocker (ARB) (61,78), statins (79,80) and histone deacetylase inhibitors (HDACis) (81,82) have all been indicated as agents that can inhibit the EMT of tumor cells or activation of stromal cells. There are a number of studies investigating the effects of these drugs and cancer treatments: For instance, metformin has been epidemiologically demonstrated to suppress tumor metastasis (83,84), whereas Nakai et al (85) demonstrated that inhibition of the renin-angiotensin system affects the prognosis of patients with advanced pancreatic cancer receiving GEM.…”

Section: Effect Of Preoperative Therapy On Pancreatic Cancer Tissuesmentioning

confidence: 99%

Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives

et al. 2017

View full text Add to dashboard Cite

Abstract. Chemotherapy for pancreatic cancer has diversified following the addition of more treatment regimens; however, in spite of this, pancreatic cancer remains a fatal disease. Preoperative (neoadjuvant) chemotherapy (NAC) or neoadjuvant chemoradiation therapy (NACRT) has been developed and implemented. For patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC), a number of clinical trials have been conducted; NACRT was demonstrated to improve resectability, R0 resection rate, overall survival rate, disease-free survival rate and even an LAPC and BRPC survival advantage over NAC. However, from the knowledge obtained from resected specimens following preoperative treatment, residual pancreatic cancer tissues following NAC are rich in chemoresistant cancer stem-like cells and epithelial-mesenchymal transition (EMT) markers. Conversely, metformin, angiotensin receptor blocker, statins and low-dose paclitaxel are well-known as drugs that inhibit EMT, which is associated with cancer stem cell-like characteristics. Although clinical effectiveness is unlikely to be achieved using one of these as an anticancer agent, it is reasonable to use these drugs for patients with comorbidities in the treatment of pancreatic cancer. Furthermore, gemcitabine (GEM) affects antitumor immunity by stimulating the expression of major histocompatibility complex class I-related chain A on the surface of cancer cells to enhance the cytotoxicity of natural killer cells. Considering EMT and antitumor immunity, there is a possibility that GEM and nanoparticle albumin-bound paclitaxel therapy is the most suitable regimen for treating pancreatic cancer. However, even as preoperative treatment progresses, R0 resection is the most important factor for the long-term survival of pancreatic cancer patients.

show abstract

Paclitaxel Interrupts TGF-β1 Signaling Between Gallbladder Epithelial Cells and Myofibroblasts

Cited by 25 publications

References 40 publications

LPS-Induced Epithelial-Mesenchymal Transition of Intrahepatic Biliary Epithelial Cells

LPS-Induced Epithelial-Mesenchymal Transition of Intrahepatic Biliary Epithelial Cells

Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report

Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives

Contact Info

Product

Resources

About